Bicycle therapeutics announces publication of article in the journal of medicinal chemistry highlighting preclinical data from bt8009 program

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting preclinical data from bt8009, a nectin-4 targeting bicycle toxin conjugate, was published in the journal of medicinal chemistry. the article, titled “discovery of bt8009: a nectin-4 targeting bicycle® toxin conjugate for
BCYC Ratings Summary
BCYC Quant Ranking